Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Synergistic insights into human health from aptamer- and antibody-based proteomic profiling.

Nature communications

Pietzner M, Wheeler E, Carrasco-Zanini J, Kerrison ND, Oerton E, Koprulu M, Luan J, Hingorani AD, Williams SA, Wareham NJ, Langenberg C.
PMID: 34819519
Nat Commun. 2021 Nov 24;12(1):6822. doi: 10.1038/s41467-021-27164-0.

Affinity-based proteomics has enabled scalable quantification of thousands of protein targets in blood enhancing biomarker discovery, understanding of disease mechanisms, and genetic evaluation of drug targets in humans through protein quantitative trait loci (pQTLs). Here, we integrate two partly...

Cite
Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nat Commun. 2021;12(1):6822doi: 10.1038/s41467-021-27164-0.
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Kerrison, N. D., Oerton, E., Koprulu, M., Luan, J., Hingorani, A. D., Williams, S. A., Wareham, N. J., & Langenberg, C. (2021). Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nature communications, 12(1), 6822. https://doi.org/10.1038/s41467-021-27164-0
Pietzner, Maik, et al. "Synergistic insights into human health from aptamer- and antibody-based proteomic profiling." Nature communications vol. 12,1 (2021): 6822. doi: https://doi.org/10.1038/s41467-021-27164-0
Pietzner M, Wheeler E, Carrasco-Zanini J, Kerrison ND, Oerton E, Koprulu M, Luan J, Hingorani AD, Williams SA, Wareham NJ, Langenberg C. Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nat Commun. 2021 Nov 24;12(1):6822. doi: 10.1038/s41467-021-27164-0. PMID: 34819519; PMCID: PMC8613205.
Copy Download .nbib Format: NLM
Mapping the serum proteome to neurological diseases using whole genome sequencing.

Nature communications

Png G, Barysenka A, Repetto L, Navarro P, Shen X, Pietzner M, Wheeler E, Wareham NJ, Langenberg C, Tsafantakis E, Karaleftheri M, Dedoussis G, Mälarstig A, Wilson JF, Gilly A, Zeggini E.
PMID: 34857772
Nat Commun. 2021 Dec 02;12(1):7042. doi: 10.1038/s41467-021-27387-1.

Despite the increasing global burden of neurological disorders, there is a lack of effective diagnostic and therapeutic biomarkers. Proteins are often dysregulated in disease and have a strong genetic component. Here, we carry out a protein quantitative trait locus...

Cite
Png G, Barysenka A, Repetto L, et al. Mapping the serum proteome to neurological diseases using whole genome sequencing. Nat Commun. 2021;12(1):7042doi: 10.1038/s41467-021-27387-1.
Png, G., Barysenka, A., Repetto, L., Navarro, P., Shen, X., Pietzner, M., Wheeler, E., Wareham, N. J., Langenberg, C., Tsafantakis, E., Karaleftheri, M., Dedoussis, G., Mälarstig, A., Wilson, J. F., Gilly, A., & Zeggini, E. (2021). Mapping the serum proteome to neurological diseases using whole genome sequencing. Nature communications, 12(1), 7042. https://doi.org/10.1038/s41467-021-27387-1
Png, Grace, et al. "Mapping the serum proteome to neurological diseases using whole genome sequencing." Nature communications vol. 12,1 (2021): 7042. doi: https://doi.org/10.1038/s41467-021-27387-1
Png G, Barysenka A, Repetto L, Navarro P, Shen X, Pietzner M, Wheeler E, Wareham NJ, Langenberg C, Tsafantakis E, Karaleftheri M, Dedoussis G, Mälarstig A, Wilson JF, Gilly A, Zeggini E. Mapping the serum proteome to neurological diseases using whole genome sequencing. Nat Commun. 2021 Dec 02;12(1):7042. doi: 10.1038/s41467-021-27387-1. PMID: 34857772; PMCID: PMC8640022.
Copy Download .nbib Format: NLM
Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the .

Diabetes

Bowker N, Hansford R, Burgess S, Foley CN, Auyeung VPW, Erzurumluoglu AM, Stewart ID, Wheeler E, Pietzner M, Gribble F, Reimann F, Bhatnagar P, Coghlan MP, Wareham NJ, Langenberg C.
PMID: 34426508
Diabetes. 2021 Nov;70(11):2706-2719. doi: 10.2337/db21-0103. Epub 2021 Aug 23.

There is considerable interest in GIPR agonism to enhance the insulinotropic and extrapancreatic effects of GIP, thereby improving glycemic and weight control in type 2 diabetes (T2D) and obesity. Recent genetic epidemiological evidence has implicated higher GIPR-mediated GIP levels...

Cite
Bowker N, Hansford R, Burgess S, et al. Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the . Diabetes. 2021;70(11):2706-2719doi: 10.2337/db21-0103.
Bowker, N., Hansford, R., Burgess, S., Foley, C. N., Auyeung, V. P. W., Erzurumluoglu, A. M., Stewart, I. D., Wheeler, E., Pietzner, M., Gribble, F., Reimann, F., Bhatnagar, P., Coghlan, M. P., Wareham, N. J., & Langenberg, C. (2021). Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the . Diabetes, 70(11), 2706-2719. https://doi.org/10.2337/db21-0103
Bowker, Nicholas, et al. "Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the ." Diabetes vol. 70,11 (2021): 2706-2719. doi: https://doi.org/10.2337/db21-0103
Bowker N, Hansford R, Burgess S, Foley CN, Auyeung VPW, Erzurumluoglu AM, Stewart ID, Wheeler E, Pietzner M, Gribble F, Reimann F, Bhatnagar P, Coghlan MP, Wareham NJ, Langenberg C. Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the . Diabetes. 2021 Nov;70(11):2706-2719. doi: 10.2337/db21-0103. Epub 2021 Aug 23. PMID: 34426508; PMCID: PMC8564402.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries